Q2 2025 Cencora Inc Earnings Call Transcript
Key Points
- Cencora Inc (COR) reported strong revenue growth of 10% and adjusted diluted EPS growth of 16% for the second quarter.
- The company raised its full-year guidance for adjusted operating income and adjusted diluted EPS, reflecting strong performance and expectations for continued growth.
- Cencora is expanding its capabilities in key markets, supporting pharmaceutical innovation and access, particularly in specialty medications.
- The integration of U.S. and European 3PL businesses has created an internationally unified network, enhancing Cencora's pharmaceutical logistics offering.
- Cencora's strategic investments in specialty areas, such as the acquisition of Retina Consultants of America, are contributing to increased gross profit margins.
- Cencora's International Healthcare Solutions segment is experiencing a period of market softness, particularly in the global specialty logistics business.
- The company noted a decline in clinical trial activity, which has been slower to rebound than expected, impacting its international segment performance.
- There is a potential risk associated with tariffs and their impact on the pharmaceutical supply chain, although Cencora has not called out any material impact yet.
- The company anticipates revenue growth to be at the lower end of its guidance range due to factors like tougher GLP-1 growth comparisons and declining sales of high-priced mail order products.
- Cencora does not anticipate further share repurchases in the near term as it focuses on deleveraging following recent acquisitions.
Hello, everyone, and thank you for joining the Cencora fiscal 2025 second-quarter results conference call. My name is Lucy, and I will be coordinating your call today. (Operator Instructions)
I will now hand over to your host, Bennett Murphy, Senior Vice President, Head of Investor Relations and Treasury to begin. Please go ahead.
Thank you. Good morning, good afternoon, and thank you all for joining us for this conference call to discuss Cencora's fiscal 2025 2nd quarter results. I am Bennett Murphy, Senior Vice President, Head of Investor Relations and Treasury. Joining me today are Bob Mauch, President and CEO; and Jim Cleary, Executive Vice President and CFO. On today's call, we'll be discussing non-GAAP financial measures.
Reconciliations of these measures to GAAP are provided in today's press release, which is available on our website at investor.cencora.com. We've also posted a slide presentation to accompany today's press release on our investor website. During
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
